Active Surveillance (AS) Articles

ORLANDO, FL USA (UroToday.com) - In this podium presentation, Dr. Laurence Klotz presented follow-up data of nearly 20 years on a large single center active surveillance cohort which included 840 men with low- or intermediate-risk prostate cancer.

BERKELEY, CA (UroToday.com) - Genetic tests have been developed for a multitude of diseases and conditions, and more new tests continue to be introduced for use in the clinical setting.

BERKELEY, CA (UroToday.com) - The value of sonography combined with color Doppler sonography and power Doppler sonography (PDS) in the detection of prostate cancer has given rise to a great many evaluations.

Signs of disease progression (28%) and conversion to active treatment without evidence of disease progression (13%) are the main reasons for discontinuation of active surveillance (AS) in men with localised prostate cancer (PCa).

Most of low grade (LG) bladder tumors will experience disease recurrence and very few of them (<2%) will experience disease progression. Therefore active surveillance (AS) for LG non-muscle invasive bladder cancer (NMIBC) has emerged.

“Active surveillance of prostate cancer in a community practice; how to measure manage and improve” is an analysis of a quality improvement initiative to enhance the utilization of active surveillance for clinically localized low risk prostate cancer in a large urology practice group. The group, Genesis Healthcare Partners, in San Diego CA, developed their active surveillance criteria in collaboration with UC San Diego, using NCCN guidelines as a template. 

The primary goal of active surveillance (AS) is to prevent overtreatment by selecting patients with low-risk prostate cancer (PCa) and closely monitoring them so that definitive treatment can be offered when needed.

SAN DIEGO, CA USA (UroToday.com) - Active surveillance (AS) is gaining momentum in this era of prostate cancer over-diagnosis and overtreatment, and many efforts are on the way to better risk-stratify patients prior to the intervention.

SAN DIEGO, CA USA (UroToday.com) - The prostate cancer screening session at the AUA 2013 in San Diego included several main themes: (1) change in practice patterns following release of the USPSTF’s PSA screening recommendations, (2) improvement of biopsy techniques by integrating MRI technology, and (3) rising rates of complications following repeat prostate biopsy.

SAN DIEGO, CA USA (UroToday.com) - Quality-of-life outcomes often serve as the metric of superiority amongst various therapies in the localized prostate cancer space.

SAN DIEGO, CA USA (UroToday.com) - A small number of patients on active surveillance for prostate cancer may progress due to occult areas of high-grade cancer missed on standard extended prostate biopsy (EB, ≤ 14 cores). Saturation biopsy (SB, ≥ 20 cores) may lead to more through sampling of the prostate and reduce the risk of missed high-grade cancers.

SAN DIEGO, CA USA (UroToday.com) - Investigators from Canada suggest that no cancer on second biopsy in men on active surveillance portends a good prognosis and may require less intensive follow-up.

Prostate cancer (PCa) patients selected for active surveillance (AS) have received information on prostate cancer PCa, treatment, knew their serum prostate specific antigen (PSA), a digital rectal examination (DRE) done and could rely on their set of biopsies to be labelled as low grade, low volume disease (by adding a radiographic/ultrasonic measurement).

The use of active surveillance (AS) is increasing for favorable-risk prostate cancer. However, there remain challenges in patient selection for AS, due to the limitations of current clinical staging.

Active surveillance (AS) for low-risk prostate cancer (PCa) appears to provide excellent long-term PCa-specific and overall survival. The choice for AS as initial treatment is mainly based on avoiding side effects from invasive treatment; but AS entails regular check-ups and the possibility of still having to switch or deciding to switch to invasive treatment.

Over the last ten years, active surveillance (AS) has become increasingly utilized for patients with low-risk prostate cancer. Appropriately selected AS patients have a 10-year prostate cancer-specific mortality (PCSM) approaching 99%.

BERKELEY, CA (UroToday.com) - More patients with localized prostate cancer elect to undergo active surveillance (AS) in order to postpone active treatment until disease progression.

SAN FRANCISCO, CA USA (UroToday.com) - Within the last decade, despite a considerable rise in the age-adjusted incidence of prostate cancer in the United States, the incidence of prostate cancer has remained stable (180 cases per 100 000 men).

Active surveillance (AS) is the most rapidly expanding management option for favorable-risk prostate cancer (PCa). Early studies suggested substantial decrements in utility (quality of life weights) from disease-related anxiety.

Traditional prostate imaging is fairly limited, and only a few imaging modalities have been used for this purpose. Until today, grey scale ultrasound was the most widely used method for the characterization of the prostatic gland, however its limitations for prostate cancer (PCa) detection are well known and hence ultrasound is primarily used to localize the prostate and facilitate template prostate biopsies.

For men with lower risk prostate cancer, there is ever-growing literature that demonstrates the oncologic safety of deferring radical treatment and opting for regular monitoring for disease progression.

Several studies have been conducted on the quality of life (QoL) in men with low risk prostate cancer (PCa) who choose active surveillance (AS). While recent reviews have shown a lack of consistency among the available QoL-studies, a few key points have been identified, including decision-making (DM)-related issues and their potential effect on QoL.

Active surveillance (AS) for the management of low-risk prostate cancer has been increasing and in the general population appears safe, allowing for a reduction in the harms of prostate cancer screening such as overtreatment.

BERKELEY, CA (UroToday.com) - Prostate cancer is a significant health burden. There will be over 238 590 new diagnoses of prostate cancer this year.